Just to put this in perspective of how great of an opportunity IPIX is compared to BNTX. BNTX has a reported net income of -170 million in the last year and is in phase 1 with its candidate. Yet has 500 million on hand and sits at $45 a share with a little less outstanding shares. Yes they have other partnerships in the works but are burning through capital at an alarming rate. With all of our potential phase 2/3 assets and barely any debt, there is no reason that we shouldn’t see at least half of this SP on any deal with a decent upfront.
(5)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links